Loading...
•
Jun 28
Hologic Q3 2025 Earnings Report
Hologic reported its financial results for the third quarter of fiscal 2025, exceeding revenue and non-GAAP diluted EPS guidance.
Key Takeaways
Hologic delivered a solid third quarter in fiscal 2025, with revenue of $1,023.8 million and non-GAAP diluted EPS of $1.08, both surpassing guidance. The company saw growth in Diagnostics and Surgical segments, with a continued rebound in Breast Health expected to drive future growth.
Revenue reached $1,023.8 million, exceeding the company's guidance range.
Non-GAAP diluted EPS was $1.08, surpassing the high end of the guidance range.
Diagnostics revenue increased by 1.8%, driven by molecular diagnostics sales.
Surgical revenue grew by 7.1%, primarily due to the acquired Gynesonics business and strong international sales.
Hologic
Hologic
Hologic Revenue by Segment
Hologic Revenue by Geographic Location
Revenue by Segment
Diagnostics Revenue
CapyFin.comMolecular Diagnostics Revenue
CapyFin.comCytology & Perinatal Revenue
CapyFin.comBlood Screening Revenue
CapyFin.comBreast Health Revenue
CapyFin.comBreast Imaging Revenue
CapyFin.comInterventional Breast Solutions Revenue
CapyFin.comGYN Surgical Revenue
CapyFin.comSkeletal Health Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
Hologic expects continued mid-single-digit growth in organic, constant currency revenue excluding COVID-19 for the fourth quarter, with non-GAAP EPS growing faster than revenue.
Positive Outlook
- Expected mid-single-digit growth in organic, constant currency revenue excluding COVID-19 for Q4 2025.
- Non-GAAP EPS is forecast to grow faster than revenue in Q4 2025.
- Tariff mitigation efforts are expected to help non-GAAP EPS growth.
- Full year fiscal 2025 revenue guidance of $4,081 million to $4,091 million.
- Full year fiscal 2025 non-GAAP EPS guidance of $4.23 to $4.26.
Challenges Ahead
- GAAP EPS for full fiscal 2025 is projected to decrease by 22.9% to 22.0% compared to the previous year.
- The acquired Gynesonics business revenue will be excluded from organic revenue for all of fiscal 2025.
- No specific negative impacts were highlighted for the upcoming quarter beyond the GAAP EPS decline.
- The report does not specify any new or increasing operational challenges.
- No explicit mention of potential market headwinds or competitive pressures in the guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income